A year after Lipitor lost its patent protection, a number companies are making headway on the...
A year after Lipitor lost its patent protection, a number companies are making headway on the next generation of medicines for reducing LDL, or "bad cholesterol." Much interest focuses on the cholesterol-regulating gene PCSK9 in the liver, with Amgen (AMGN) (see [[here]]) and Pfizer (PFE) yesterday presenting data showing that their drugs performed well in mid-stage trials. Sanofi (SNY) and partner Regeneron (REGN) announced a massive Phase III trial for their treatment.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs